CFM
BBIO icon

Compass Financial Management’s BridgeBio Pharma BBIO Stock Holding History

Compass Financial Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.1K Buy
+147
New +$10.3K ﹤0.01% 1014

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Compass Financial Management's BBIO Position: Q2 2026 in Review

Compass Financial Management opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 147 shares worth $12.1K. The stake represents ﹤0.01% of the portfolio and ranks #1014 among its holdings.

439 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Compass Financial Management held 147 shares of BridgeBio Pharma worth $12.1K as of Q2 2026.
  • BridgeBio Pharma was a new Compass Financial Management position in Q2 2026.
  • BridgeBio Pharma made up ﹤0.01% of Compass Financial Management's portfolio in Q2 2026, its #1014 holding.
  • 439 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Compass Financial Management's 13F filing for Q2 2026, filed 12 Aug 2026.